A string of recent clinical wins with partner Sanofi makes Regeneron look like a winner, but this Fool believes investors will find these two companies better suited to their investing goals.
A string of recent clinical wins with partner Sanofi makes Regeneron look like a winner, but this Fool believes investors will find these two companies better suited to their investing goals.